Comparison of the Bioaccessibility of Two Formulations of Magnesium Bisglycinate Using an In Vitro Simulation of the Upper Gastrointestinal Tract.

IF 3.1 Q3 NUTRITION & DIETETICS
Journal of Dietary Supplements Pub Date : 2026-01-01 Epub Date: 2026-09-08 DOI:10.1080/19390211.2026.2727023
Cindy Duysburgh, Marlies Govaert, Peter Azmi, Robert Finn, Nylen Simmons, Massimo Marzorati
{"title":"Comparison of the Bioaccessibility of Two Formulations of Magnesium Bisglycinate Using an In Vitro Simulation of the Upper Gastrointestinal Tract.","authors":"Cindy Duysburgh, Marlies Govaert, Peter Azmi, Robert Finn, Nylen Simmons, Massimo Marzorati","doi":"10.1080/19390211.2026.2727023","DOIUrl":null,"url":null,"abstract":"<p><p>Modern diets are often deficient in magnesium, making magnesium supplementation an important consideration for overall human health. However, the efficiency of magnesium release and absorption in the small intestine varies among different magnesium formulations. The objective of this study was therefore to assess whether using the same magnesium salt type in different formulations could affect efficiency of magnesium release and passive diffusion in the simulated human intestine. This study utilized an <i>in vitro</i> simulation of the upper gastrointestinal tract under fasted conditions to evaluate capsule dissolution and levels of bioaccessible and dialyzable magnesium during transit for two magnesium bisglycinate supplements containing a similar magnesium content (Chelamax<sup>®</sup> and Albion<sup>®</sup>). For this purpose, the validated Simulator of the Human Intestinal Microbial Ecosystem (SHIME<sup>®</sup>) technology platform was used and magnesium fractions were determined by inductively coupled plasma optical emission spectroscopy following sample extraction. Analytical validation proved that the model was fit for purpose (94-102% recovery, RSD ≤ 2.4%, R2 > 0.999, LOQ 0.04 mg/kg). Visual capsule scoring found that the Chelamax<sup>®</sup> product dissolved later in gastrointestinal transit than the Albion<sup>®</sup> product. Magnesium bioaccessibility was higher for the Chelamax<sup>®</sup> versus Albion<sup>®</sup> product in early phases of the gastrointestinal tract (i.e. duodenum), resulting in 17% higher overall Mg availability after the small intestinal incubation was complete. The level of dialyzable magnesium at the end of the small intestinal incubation was significantly higher with the Chelamax<sup>®</sup> versus Albion<sup>®</sup> product (53 mg vs. 39 mg; p = 0.0009). These results demonstrate that the Chelamax<sup>®</sup> product showed significantly higher <i>in vitro</i> efficiency of potentially absorbable magnesium, even upon using the same magnesium salt type, suggesting the crucial role of product formulation. Even though a proven valid <i>in vitro</i> methodology for the prediction of effectiveness of magnesium availability was used, future <i>in vivo</i> studies should confirm these findings.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"690-704"},"PeriodicalIF":3.1000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dietary Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19390211.2026.2727023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Modern diets are often deficient in magnesium, making magnesium supplementation an important consideration for overall human health. However, the efficiency of magnesium release and absorption in the small intestine varies among different magnesium formulations. The objective of this study was therefore to assess whether using the same magnesium salt type in different formulations could affect efficiency of magnesium release and passive diffusion in the simulated human intestine. This study utilized an in vitro simulation of the upper gastrointestinal tract under fasted conditions to evaluate capsule dissolution and levels of bioaccessible and dialyzable magnesium during transit for two magnesium bisglycinate supplements containing a similar magnesium content (Chelamax® and Albion®). For this purpose, the validated Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) technology platform was used and magnesium fractions were determined by inductively coupled plasma optical emission spectroscopy following sample extraction. Analytical validation proved that the model was fit for purpose (94-102% recovery, RSD ≤ 2.4%, R2 > 0.999, LOQ 0.04 mg/kg). Visual capsule scoring found that the Chelamax® product dissolved later in gastrointestinal transit than the Albion® product. Magnesium bioaccessibility was higher for the Chelamax® versus Albion® product in early phases of the gastrointestinal tract (i.e. duodenum), resulting in 17% higher overall Mg availability after the small intestinal incubation was complete. The level of dialyzable magnesium at the end of the small intestinal incubation was significantly higher with the Chelamax® versus Albion® product (53 mg vs. 39 mg; p = 0.0009). These results demonstrate that the Chelamax® product showed significantly higher in vitro efficiency of potentially absorbable magnesium, even upon using the same magnesium salt type, suggesting the crucial role of product formulation. Even though a proven valid in vitro methodology for the prediction of effectiveness of magnesium availability was used, future in vivo studies should confirm these findings.

用体外模拟上胃肠道比较两种双甘氨酸镁制剂的生物可及性。
现代饮食通常缺乏镁,因此补充镁是人类整体健康的重要考虑因素。然而,镁在小肠中的释放和吸收效率因镁制剂的不同而不同。因此,本研究的目的是评估在不同配方中使用相同类型的镁盐是否会影响镁在模拟人体肠道中的释放和被动扩散效率。本研究利用体外模拟禁食条件下的上消化道来评估两种含镁量相似的双甘氨酸镁补充剂(Chelamax®和Albion®)在运输过程中的胶囊溶出度、生物可及性和可透析性镁的水平。为此,使用经过验证的人类肠道微生物生态系统模拟器(SHIME®)技术平台,并在样品提取后通过电感耦合等离子体发射光谱测定镁组分。分析验证表明,该模型符合要求(回收率94 ~ 102%,RSD≤2.4%,R2 0 0.999, LOQ 0.04 mg/kg)。视觉胶囊评分发现,Chelamax®产品比Albion®产品在胃肠道运输中溶解得晚。与Albion®产品相比,Chelamax®产品在胃肠道(即十二指肠)的早期阶段镁的生物可及性更高,在小肠孵育完成后,镁的总可利用性高出17%。与Albion®产品相比,Chelamax®产品在小肠孵育结束时的可透析镁水平显著更高(53 mg对39 mg, p = 0.0009)。这些结果表明,即使使用相同的镁盐类型,Chelamax®产品的潜在可吸收镁的体外效率也显著提高,这表明产品配方的关键作用。尽管使用了一种被证明有效的体外方法来预测镁可利用性的有效性,但未来的体内研究应该证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Dietary Supplements
Journal of Dietary Supplements Agricultural and Biological Sciences-Food Science
CiteScore
6.10
自引率
0.00%
发文量
34
期刊介绍: The Journal of Dietary Supplements (formerly the Journal of Nutraceuticals, Functional & Medical Foods) has been retitled to reflect the bold departure from a traditional scientific journal presentation to a leading voice for anyone with a stake in dietary supplements. The journal addresses important issues that meet the broad range of interests from researchers, regulators, marketers, educators, and health professionals from academic, governmental, industry, healthcare, public health, and consumer education sectors. This vital tool not only presents scientific information but interprets it - helping you more readily pass it on to your students, patients, clients, or company.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书